Cost-effectiveness of vaccination against pneumococcal infection of adults at risk within the federal and regional programs-Reference-Cited by-同舟云学术

Cost-effectiveness of vaccination against pneumococcal infection of adults at risk within the federal and regional programs

Published:2019-12-08 Issue:4 Volume:11 Page:6-18
ISSN:2499-9865
Container-title:Journal Infectology
language:
Short-container-title:test

Author:

Rudakova A. V.¹,Briko N. I.²,Lobzin Yu. V.³,Namazova-Baranova L. S.⁴,Drapkina O. M.⁵,Avdeev S. N.⁶,Drozdova L. Yu.⁵,Ignatova G. L.⁷,Koroleva I. S.⁸,Korshunov V. A.²,Kostinov M. P.⁹

Affiliation:

1. Pediatric Research and Clinical Center for Infectious Diseases; Saint-Petersburg State Chemical Pharmaceutical University

2. First Moscow State Medical University named after I.M. Sechenov

3. Pediatric Research and Clinical Center for Infectious Diseases

4. Russian National Research Medical University named after N.I. Pirogov

5. National Medical Research Center for Preventive Medicine

6. First Moscow State Medical University named after I.M. Sechenov; Research Institute of Pulmonology

7. South Ural State Medical University

8. Central Research Institute of Epidemiology

9. Research Institute of Vaccines and Serums named after I.I. Mechnikov

Publisher

SPRIDA

Subject

Infectious Diseases

Reference27 articles.

1. Shea K. Rates of Pneumococcal Disease in Adults With Chronic Medical Conditions Pneumococcal Disease in Adults [Text] / K. Shea, J. Edelsberg, D. Weycker, et al. // OFID. 2014. - P. 1-9.

2. Kuchenbecker U., Chase D., Reichert A., Schiffner-Rohe J., Atwood M. Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany // PLoS ONE 2018; 13(5): e0197905.

3. Morton, J. B. Risk stacking of pneumococcal vaccination indications increases mortality in unvaccinated adults with Streptococcus pneumoniae infections [Text] / J. B. Morton., H. J. Morrill, K. L. LaPlante, A. R. Caffrey // Vaccine. 2017. V.35.-№13.-P. 1692-1697.

4. Ewig S. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality [Text] / S. Ewig, N. Birkner, R. Strauss, R. Schaefer, et al. // Thorax. 2009.- V. 64.- P. 1062-1069.

5. Federal'nyj centr gigieny i epidemiologii.- Svedeniya ob infekcionnyh i para-zitarnyh zabolevaniyah.- Forma 2.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Decade of Experience in the use of 13-Valent Conjugated Polysaccharide Pneumococcal Vaccine in Russian Federation;Epidemiology and Vaccinal Prevention;2023-09-21

2. Analysis of medical and economic efficiency of vaccine prevention of respiratory diseases among builders of the Amur Gas Processing Plant using expert assessments and methods of predictive modeling;Bulletin Physiology and Pathology of Respiration;2022-09-21

3. Vaccination against pneumococcal infection in adults from risk groups;Tuberculosis and Lung Diseases;2020-06-03

4. The prevalence of circulating S. pneumoniae serotypes in people older than 18 years: healthy carriers, patients with acute otitis media, community-acquired pneumonia, and invasive pneumococcal infections (epidemiological study «SPECTRUM»);Clinical Microbiology and Antimicrobial Chemotherapy;2019